FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944446972> ?p ?o ?g. }

• W2944446972 endingPage "94" @default.
• W2944446972 startingPage "83" @default.
• W2944446972 abstract "Background and purpose Nasopharyngeal carcinoma (NPC) patients can be separated into two risk subgroups according to tumor responses to induction chemotherapy (IC). We aimed to elucidate the optimal cumulative cisplatin dose (CCD) of concurrent chemoradiotherapy (CCRT) for different NPC patient subgroups. Participants and methods A total of 990 patients with incident NPC diagnosed between 2008 and 2017 treated with IC plus CCRT were included in our observational study. The clinicopathological features of patients with different tumor responses were compared using the Chi-square test or Fisher’s exact test. Prognosis was assessed using a multivariate Cox proportional hazards model. In addition, acute and late toxicities were compared between different CCD groups. Results After IC, 761/990 (76.9%) patients had a complete tumor response (CR)/partial response (PR) and 229 (23.1%) had stable disease (SD)/disease progression (PD). An unsatisfactory tumor response (SD/PD) after IC correlated with poor clinical outcome (3-year PFS 61.4% vs. 83.2%, P < 0.001 and 3-year LRFS 80.9% vs. 94.5%, P < 0.001). Patients who achieved CR/PR after IC received a CCD >200 mg/m2 and showed higher 3-year PFS and DMFS rates than those receiving a CCD <100 mg/m2 (PFS: 85.4% vs. 77.9%, P = 0.045; DMFS: 89.4% vs. 77.9%, P = 0.015). Multivariate analysis also showed that CCD was an independent prognostic factor for PFS and DMFS in CR/PR subgroup. Moreover, the medium dose group showed similar efficacy as high dose group but was associated with fewer grade 1–4 acute toxicities. However, application of different CCD didn’t result in significantly different survival outcomes in SD/PD subgroup. Conclusions Tumor response to IC was an independent prognostic factor for patients with NPC. For the patients who achieved CR/PR after IC, patients receiving high CCD showed significantly improved 3-year PFS and DMFS compared with patients receiving low CCD. Balancing toxicity and efficacy, 200 mg/m2 seemed to be the optimal dose in the CR/PR groups. However, enhancement of CCD did not provide survival benefit for patients who achieved SD/PD after IC, and treatment options for these patients require further consideration." @default.
• W2944446972 created "2019-05-16" @default.
• W2944446972 creator A5004040364 @default.
• W2944446972 creator A5011622378 @default.
• W2944446972 creator A5030927144 @default.
• W2944446972 creator A5041675324 @default.
• W2944446972 creator A5057532517 @default.
• W2944446972 creator A5058091307 @default.
• W2944446972 creator A5061152137 @default.
• W2944446972 creator A5062913497 @default.
• W2944446972 creator A5070904016 @default.
• W2944446972 creator A5078326314 @default.
• W2944446972 creator A5080995648 @default.
• W2944446972 creator A5082788358 @default.
• W2944446972 creator A5083022490 @default.
• W2944446972 creator A5085809215 @default.
• W2944446972 creator A5086436541 @default.
• W2944446972 creator A5087079893 @default.
• W2944446972 creator A5088118784 @default.
• W2944446972 creator A5089405590 @default.
• W2944446972 creator A5090814347 @default.
• W2944446972 creator A5091374985 @default.
• W2944446972 date "2019-08-01" @default.
• W2944446972 modified "2023-10-16" @default.
• W2944446972 title "Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response" @default.
• W2944446972 cites W1920623440 @default.
• W2944446972 cites W1973776601 @default.
• W2944446972 cites W1982667648 @default.
• W2944446972 cites W1987840462 @default.
• W2944446972 cites W2014157185 @default.
• W2944446972 cites W2014401523 @default.
• W2944446972 cites W2017286592 @default.
• W2944446972 cites W2019607817 @default.
• W2944446972 cites W2024847643 @default.
• W2944446972 cites W2025402420 @default.
• W2944446972 cites W2037357991 @default.
• W2944446972 cites W2044736010 @default.
• W2944446972 cites W2046244249 @default.
• W2944446972 cites W2076801008 @default.
• W2944446972 cites W2078682598 @default.
• W2944446972 cites W2079535829 @default.
• W2944446972 cites W2084142985 @default.
• W2944446972 cites W2125919881 @default.
• W2944446972 cites W2133134887 @default.
• W2944446972 cites W2148900467 @default.
• W2944446972 cites W2151645021 @default.
• W2944446972 cites W2160982012 @default.
• W2944446972 cites W2166243031 @default.
• W2944446972 cites W2202977982 @default.
• W2944446972 cites W2256976018 @default.
• W2944446972 cites W2327306345 @default.
• W2944446972 cites W2338224394 @default.
• W2944446972 cites W2476849670 @default.
• W2944446972 cites W2526747727 @default.
• W2944446972 cites W2585845563 @default.
• W2944446972 cites W2762585842 @default.
• W2944446972 cites W2769868297 @default.
• W2944446972 cites W2771980227 @default.
• W2944446972 cites W2779452291 @default.
• W2944446972 doi "https://doi.org/10.1016/j.radonc.2019.04.020" @default.
• W2944446972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31078941" @default.
• W2944446972 hasPublicationYear "2019" @default.
• W2944446972 type Work @default.
• W2944446972 sameAs 2944446972 @default.
• W2944446972 citedByCount "39" @default.
• W2944446972 countsByYear W29444469722020 @default.
• W2944446972 countsByYear W29444469722021 @default.
• W2944446972 countsByYear W29444469722022 @default.
• W2944446972 countsByYear W29444469722023 @default.
• W2944446972 crossrefType "journal-article" @default.
• W2944446972 hasAuthorship W2944446972A5004040364 @default.
• W2944446972 hasAuthorship W2944446972A5011622378 @default.
• W2944446972 hasAuthorship W2944446972A5030927144 @default.
• W2944446972 hasAuthorship W2944446972A5041675324 @default.
• W2944446972 hasAuthorship W2944446972A5057532517 @default.
• W2944446972 hasAuthorship W2944446972A5058091307 @default.
• W2944446972 hasAuthorship W2944446972A5061152137 @default.
• W2944446972 hasAuthorship W2944446972A5062913497 @default.
• W2944446972 hasAuthorship W2944446972A5070904016 @default.
• W2944446972 hasAuthorship W2944446972A5078326314 @default.
• W2944446972 hasAuthorship W2944446972A5080995648 @default.
• W2944446972 hasAuthorship W2944446972A5082788358 @default.
• W2944446972 hasAuthorship W2944446972A5083022490 @default.
• W2944446972 hasAuthorship W2944446972A5085809215 @default.
• W2944446972 hasAuthorship W2944446972A5086436541 @default.
• W2944446972 hasAuthorship W2944446972A5087079893 @default.
• W2944446972 hasAuthorship W2944446972A5088118784 @default.
• W2944446972 hasAuthorship W2944446972A5089405590 @default.
• W2944446972 hasAuthorship W2944446972A5090814347 @default.
• W2944446972 hasAuthorship W2944446972A5091374985 @default.
• W2944446972 hasConcept C126322002 @default.
• W2944446972 hasConcept C143998085 @default.
• W2944446972 hasConcept C151032500 @default.
• W2944446972 hasConcept C2776611710 @default.
• W2944446972 hasConcept C2776694085 @default.
• W2944446972 hasConcept C2778239845 @default.
• W2944446972 hasConcept C2778424827 @default.
• W2944446972 hasConcept C2778997737 @default.

• next